2025
SJR Q1
JCR Q1 · 4,3
24 matched articles
SCIE
Journal detail
Antiviral Research
- Publisher
- Elsevier B.V.
- Country
- Netherlands · Western Europe
- Type
- journal
- ISSN
-
0166354218729096
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 1,353
- Quartile Q1
- H-Index 162
- Cites/doc 4,29
- Docs (3y) 545
- Cites (3y) 2.355
Clarivate
Web of Science · JCR · 2025
- JCR Q Q1
- JIF 4,3
- 5Y JIF 4,3
- JCI 1,24
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Pharmacology Q1
- Virology Q1
WoS categories
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q1 | 1,353 | 4,3 | 4,3 | 1,24 | Q1 | 162 |
| 2024 | Q1 | Q1 | 1,195 | 4 | 4,3 | 1,31 | Q1 | 157 |
| 2023 | Q1 | Q1 | 1,5 | 4,5 | 5 | 1,75 | Q1 | 157 |
| 2022 | Q1 | Q1 | 1,701 | 7,6 | 5,8 | 1,69 | Q1 | 157 |
| 2021 | Q1 | Q1 | 2,213 | 10,1 | 7,4 | 1,94 | Q1 | 157 |
| 2020 | Q1 | Q1 | 2,052 | 6 | 5,8 | 1,49 | Q1 | 157 |
| 2019 | Q1 | Q1 | 1,596 | 4,1 | 3,9 | 1,38 | Q1 | 157 |
| 2018 | — | Q1 | — | 4,1 | 4,1 | 1,41 | Q1 | — |
| 2017 | Q1 | Q1 | 1,925 | 4,3 | 4,2 | 1,26 | Q1 | 157 |
| 2016 | Q1 | Q1 | 2,053 | 4,3 | 3,8 | — | — | 157 |
| 2015 | Q1 | Q1 | 2,06 | 4,9 | 4,1 | — | — | 157 |
| 2014 | Q1 | Q1 | 1,653 | 3,9 | 3,8 | — | — | 157 |
| 2013 | Q1 | Q1 | 1,516 | 3,4 | 3,9 | — | — | 157 |
| 2012 | Q1 | Q1 | 1,421 | 3,9 | 3,7 | — | — | 157 |
| 2011 | Q1 | Q1 | 1,616 | 4,3 | 3,9 | — | — | 157 |
| 2010 | Q1 | Q1 | 1,409 | 4,4 | 4 | — | — | 157 |
| 2009 | — | Q1 | — | 3,6 | 3,6 | — | — | — |
| 2008 | — | Q1 | — | 3,6 | 3,5 | — | — | — |
| 2007 | — | Q1 | — | 3,4 | 3,2 | — | — | — |
| 2006 | — | Q2 | — | 2,9 | — | — | — | — |
| 2005 | — | Q1 | — | 3,4 | — | — | — | — |
| 2004 | — | Q1 | — | 3,3 | — | — | — | — |
| 2003 | — | Q1 | — | 3,2 | — | — | — | — |
| 2002 | — | Q1 | — | 2,9 | — | — | — | — |
| 2001 | — | Q2 | — | 1,9 | — | — | — | — |
| 2000 | — | Q1 | — | 2,8 | — | — | — | — |
| 1999 | — | Q1 | — | 2,5 | — | — | — | — |
| 1998 | — | Q1 | — | 2,2 | — | — | — | — |
| 1997 | — | Q1 | — | 2,3 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q1 | 95/356 |
| 2025 | VIROLOGY | SCIE | Q1 | Q1 | 7/44 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 83/352 |
| 2024 | VIROLOGY | SCIE | Q1 | Q1 | 10/42 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 60/354 |
| 2023 | VIROLOGY | SCIE | Q1 | Q1 | 9/41 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 19/278 |
| 2022 | VIROLOGY | SCIE | Q1 | Q1 | 6/36 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 16/279 |
| 2021 | VIROLOGY | SCIE | Q1 | Q1 | 6/37 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 35/276 |
| 2020 | VIROLOGY | SCIE | Q1 | Q1 | 8/37 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 56/271 |
| 2019 | VIROLOGY | SCIE | Q2 | Q1 | 11/37 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 50/267 |
| 2018 | VIROLOGY | SCIE | Q1 | Q1 | 9/36 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 32/261 |
| 2017 | VIROLOGY | SCIE | Q2 | Q1 | 9/35 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 38/257 |
| 2016 | VIROLOGY | SCIE | Q1 | — | 7/34 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 22/255 |
| 2015 | VIROLOGY | SCIE | Q1 | — | 4/33 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 42/255 |
| 2014 | VIROLOGY | SCIE | Q2 | — | 9/33 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 58/256 |
| 2013 | VIROLOGY | SCIE | Q2 | — | 11/33 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 45/261 |
| 2012 | VIROLOGY | SCIE | Q1 | — | 8/34 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 36/261 |
| 2011 | VIROLOGY | SCIE | Q1 | — | 7/32 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 34/252 |
| 2010 | VIROLOGY | SCIE | Q1 | — | 7/33 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 50/237 |
| 2009 | VIROLOGY | SCIE | Q2 | — | 8/30 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 49/219 |
| 2008 | VIROLOGY | SCIE | Q2 | — | 7/27 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 49/205 |
| 2007 | VIROLOGY | SCIE | Q2 | — | 8/25 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 56/199 |
| 2006 | VIROLOGY | SCIE | Q2 | — | 11/23 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 43/193 |
| 2005 | VIROLOGY | SCIE | Q2 | — | 6/23 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 40/187 |
| 2004 | VIROLOGY | SCIE | Q2 | — | 7/22 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 36/185 |
| 2003 | VIROLOGY | SCIE | Q2 | — | 8/23 |
| 2002 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 40/188 |
| 2002 | VIROLOGY | SCIE | Q2 | — | 9/24 |
| 2001 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 56/186 |
| 2001 | VIROLOGY | SCIE | Q3 | — | 14/25 |
| 2000 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 32/181 |
| 2000 | VIROLOGY | SCIE | Q2 | — | 12/28 |
| 1999 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 34/175 |
| 1999 | VIROLOGY | SCIE | Q2 | — | 9/26 |
| 1998 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 33/178 |
| 1998 | VIROLOGY | SCIE | Q2 | — | 9/25 |
| 1997 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 28/157 |
| 1997 | VIROLOGY | SCIE | Q2 | — | 9/24 |